<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>ADAMTS13, recombinant: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">ADAMTS13, recombinant: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">ADAMTS13, recombinant: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="143412" href="/d/html/143412.html" rel="external">see "ADAMTS13, recombinant: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="143495" href="/d/html/143495.html" rel="external">see "ADAMTS13, recombinant: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58895128"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adzynma</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58825551"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F58895615"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Calculate administration dose and volume based on the patient's body weight using the actual potency (and not the nominal potency) as printed on ADAMTS13 (recombinant) vial. Each vial is labeled with the actual ADAMTS13 activity (potency is measured in international units).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0fb837f3-3322-4966-aa5a-3065f0e646ab">Congenital thrombotic thrombocytopenic purpura</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital thrombotic thrombocytopenic purpura:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prophylactic therapy: IV:</b> 40 units/kg once every other week; may adjust to 40 units/kg once weekly based on prior prophylactic regimen or clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>On demand therapy: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment day 1:</i>
<b>IV:</b> 40 units/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment day 2:</i>
<b>IV:</b> 20 units/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment day 3 and beyond:</i>
<b> IV:</b> 15 units/kg once daily until 2 days after acute event is resolved.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58895617"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F58895618"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dot drugH1Div" id="F58895619"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Hypersensitivity/severe allergic reaction: Immediately discontinue ADAMTS13 (recombinant) administration and provide appropriate supportive management if signs/symptoms of severe allergic reactions occur.</p></div>
<div class="block doe drugH1Div" id="F58895616"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F58895363"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="143412" href="/d/html/143412.html" rel="external">see "ADAMTS13, recombinant: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0fb837f3-3322-4966-aa5a-3065f0e646ab">Congenital thrombotic thrombocytopenic purpura</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital thrombotic thrombocytopenic purpura (cTTP): Note:</b> Calculate dose and volume for administration using the actual potency printed on the vial, not the nominal potency.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylactic therapy</i>: Children ≥2 years and Adolescents: IV: 40 units/kg/dose once every other week; may increase frequency to once weekly based on prior prophylactic regimen or clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>On-demand therapy (treatment of acute event)</i>: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Day 1: IV: 40 units/kg once.</p>
<p style="text-indent:-2em;margin-left:6em;">Day 2: IV: 20 units/kg once.</p>
<p style="text-indent:-2em;margin-left:6em;">Day 3 and beyond: IV: 15 units/kg/dose once daily; continue for 2 days after the acute event has resolved.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58895367"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: IV: No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F58895368"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: IV: No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F58833224"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (13%), diarrhea (17%), nausea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (31%), migraine (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (10%)</p></div>
<div class="block coi drugH1Div" id="F58825461"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of life-threatening hypersensitivity reactions to ADAMTS13 (recombinant) or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F58895606"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic-type hypersensitivity including anaphylactic reactions may occur with ADAMTS13 (recombinant). Inform patients of early signs of hypersensitivity, including but not limited to tachycardia, chest tightness, wheezing and/or acute respiratory distress, hypotension, generalized urticaria, pruritus, rhinoconjunctivitis, angioedema, lethargy, nausea, vomiting, paresthesia, and/or restlessness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunogenicity: ADAMTS13 (recombinant) has a potential for immunogenicity. Patients may develop neutralizing antibodies, which may result in a decreased or lack of response to ADAMTS13. Neutralizing antibodies were not reported in the congenital thrombotic thrombocytopenic purpura (cTTP) clinical trials and all subjects had been previously exposed to ADAMTS13 via plasma-based products. There are no data on immunogenicity with ADAMTS13 (recombinant) in previously untreated patients. Antibodies to host cell proteins may develop, which could potentially result in adverse reactions. Data are lacking on immunogenicity to host cell proteins in previously untreated patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12534540','lexi-content-ref-10985636','lexi-content-ref-7746084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12534540','lexi-content-ref-10985636','lexi-content-ref-7746084'])">Ref</a></span>). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3960626','lexi-content-ref-6423951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3960626','lexi-content-ref-6423951'])">Ref</a></span>). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F58895129"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adzynma: ADAMTS13 (recombinant)-krhn 500 units, ADAMTS13 (recombinant)-krhn 1500 units [latex free; contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F58895127"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block accres drugH1Div" id="F58895594"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">ADAMTS13 (recombinant) is available through specialty pharmacies/distributors and various specialty institutions/accounts. Examples from the manufacturer may be found at: https://www.adzynma.com/how-to-order.</p></div>
<div class="block adm drugH1Div" id="F58895620"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer at a rate of 2 to 4 mL/minute. Gently remove air bubbles from syringe prior to administration. A syringe pump may be used to control administration rate. Do not administer ADAMTS13 (recombinant) in the same infusion line at the same time with other medications.</p></div>
<div class="block admp drugH1Div" id="F58895373"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only. Gently remove air bubbles from syringe prior to administration. Infuse at a rate of 2 to 4 mL/minute. A syringe pump may be used to control administration rate. Do not administer ADAMTS13 in the same infusion line at the same time with other medications. If severe hypersensitivity reactions including anaphylaxis occur, immediately discontinue infusion and provide appropriate supportive care.</p></div>
<div class="block use drugH1Div" id="F58825460"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Congenital thrombotic thrombocytopenic purpura:</b> Prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).</p></div>
<div class="block mst drugH1Div" id="F58895592"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Adzynma may be confused with Adthyza, Adzenys, Akynzeo, Andexxa.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58851012"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58851009"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F58895602"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Data related to the use of ADAMTS13 (recombinant) in pregnant patients are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36546627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36546627'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated thrombotic thrombocytopenic purpura (TTP) is associated with adverse pregnancy outcomes. Agents other than recombinant ADAMTS13 are currently recommended to treat TTP during pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37586700','lexi-content-ref-32914526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37586700','lexi-content-ref-32914526'])">Ref</a></span>).</p></div>
<div class="block brc drugH1Div" id="F58895603"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ADAMTS13 (recombinant) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F58895623"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity (eg, tachycardia, chest tightness, wheezing, acute respiratory distress, hypotension, generalized urticaria, pruritus, rhinoconjunctivitis, angioedema, lethargy, nausea, vomiting, paresthesia, restlessness) and for the development of immunogenicity (development of neutralizing antibodies or antibodies to host cell proteins).</p></div>
<div class="block pha drugH1Div" id="F58895610"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">ADAMTS13 (recombinant) is a bivariant human recombinant form of endogenous ADAMTS13 (a plasma zinc metalloprotease with thrombospondin motifs 13), which regulates von Willebrand factor (VWF) activity by cleaving large and ultra-large VWF multimers into smaller units, reducing VWF platelet binding properties and therefore the propensity to form microthrombi.</p></div>
<div class="block phk drugH1Div" id="F58895611"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Adults: Following a single IV dose of 5 units/kg, 20 units/kg, or 40 units/kg, dose-related increases in individual ADAMTS13 activity were observed and reached maximum activity at ≤1 hour post infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Adults: Following an IV dose (at the recommended dose), von Willebrand factor (VWF): antigen and VWF:ristocetin cofactor activity are transiently decreased for 1 to 2 days with a 15% to 25% change from baseline; duration of ADAMTS13 activity above 10%: 5.8 days (range: 4.5 to ~9 days).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: ~48 hours (40 units/kg dose; range: ~30 to ~90 hours); mean residence time: ~64 hours (40 units/kg dose; range: ~45 to 113 hours).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Takeda.1">
<a name="Takeda.1"></a>Adzynma (ADAMTS13 Recombinant) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36546627">
<a name="36546627"></a>Asmis LM, Serra A, Krafft A, et al. Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura. <i>N Engl J Med</i>. 2022;387(25):2356-2361. doi:10.1056/NEJMoa2211113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/36546627/pubmed" id="36546627" target="_blank">36546627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37586700">
<a name="37586700"></a>Scully M, Rayment R, Clark A, et al; BSH Committee. A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. <i>Br J Haematol</i>. 2023;203(4):546-563. doi:10.1111/bjh.19026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/37586700/pubmed" id="37586700" target="_blank">37586700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32914526">
<a name="32914526"></a>Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. <i>J Thromb Haemost</i>. 2020;18(10):2496-2502. doi:10.1111/jth.15010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adamts13-recombinant-drug-information/abstract-text/32914526/pubmed" id="32914526" target="_blank">32914526</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 143378 Version 10.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
